

Announcing New Clinical Trials

NAME OF INSTITUTION:

Novartis Pharmaceuticals

TRIAL NUMBER: NCT00940602

Title of Trial or Description:

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)

A Multi-center, Randomized, Double-blind, Placebo-controlled Clinical Trial of Deferasirox in Patients With Myelodysplastic Syndromes (Low/Int-1 Risk) and Transfusional Iron Overload

Currently Recruiting Participants.

The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload.

Contact the Novartis Clinical Trials Hotline at 800-340-6843 or go to www.clinicaltrials.gov for additional information and to view the active sites.

NAME OF INSTITUTION:

Onconova Therapeutics

TRIAL NUMBER: NCT01241500

Title of Trial or Description:

A Phase III Study of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients Who Have Failed or Relapsed After Azacitidine or Decitabine Treatment (ONTIME)

Currently Recruiting Participants.

The primary purpose of this study is to compare overall survival (OS) in patients receiving ON 01910.Na infusion administered every other week + best supportive care (BSC) to OS of patients receiving BSC in a population of patients with MDS with excess blasts (5% to 30% bone marrow blasts) having failed, being intolerant, or relapsing after azacitidine or decitabine treatment.

Contact the Onconova Clinical Trials Helpline at 1.855.609.6564 toll free or go to www.clinicaltrials.gov for additional information.

NAME OF INSTITUTION:

Celgene Corporation

TRIAL NUMBER: NCT01029262

Title of Trial or Description:

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Low Risk Myelodysplastic Syndrome (MDS) Without Del 5Q (MDS-005)

Currently Recruiting Participants.

The primary purpose of this study is to compare the efficacy of Lenalidomide (Revlimid®) versus placebo in achieving red blood cell transfusion independence in the overall study population and in a pre-specified subgroup of patients with an erythroid differentiation gene expression signature predictive of Lenalidomide response.

Access www.clinicaltrials.gov for additional information.